INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Ocular Disease Requiring Surgery
Interventions
DRUG

DEXTENZA®

DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.

Trial Locations (3)

93401

California Retina Consultants, San Luis Obispo

93446

California Retina Consultants, Paso Robles

93454

California Retina Consultants, Santa Maria

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Nathan Steinle

OTHER

NCT04529512 - INtravitreal and Aqueous Dexamethasone Levels After DEXtenza | Biotech Hunter | Biotech Hunter